FLOW SUMMARY

Sentiment on Mesoblast (MESO) is characterized by a bullish/speculative bias, as evidenced by a Put/Call Ratio of 0.56 (maturity 2026-09-18), indicating a dominance of call options. This suggests a risk appetite from market participants. However, institutional activity in dark pools remains subdued, with OTC volume of only 71,596 shares and negligible notional over the past week, limiting the impact of discreet flows. In summary, aggregated signals indicate a MIXED bias, with positive speculative sentiment contrasting with a lack of significant institutional OTC flows.

TECHNICAL AND VOLUMETRIC STRUCTURE

The MESO stock is currently trading at $16.84, above its 20-day SMA at $16.15 and 200-day SMA at $16.04, signaling an underlying bullish trend in the short and medium term. The RSI(14) at 58.92 is neutral, with no indication of overbought or oversold conditions. Key resistance to watch is at $19.36 (6M resistance), while major support is at $13.05 (6M support). Over the last 20 days, MESO has recorded a notable performance of +19.2%, but has declined by -1.7% over the last 5 days, including a slight intraday pullback of -0.95% on August 24th despite announced revenues of $115M. Today's volume is low, at 59% of its monthly average, which does not signal strong institutional selling pressure at this time. The earnings release, while positive in terms of revenue, led to profit-taking, which is consistent with the exhausted momentum signal after a strong rally.

SCENARIOS & CATALYSTS

On the main horizon (medium term, 20-60 days):

BULLISH Scenario (Probability 60%): The stock is currently consolidating after a strong rally and earnings release. However, the high fundamental potential, anchored by an analyst consensus at $35.00 (+107.8% upside), and MESO's relative outperformance against the S&P 500 over 20 days (+12.0pts) and 3 months (+12.5pts) should take over. A confirmed close above $17.00 could mark the end of the consolidation phase and reignite bullish momentum towards the $19.36 resistance, then the top of the annual range. * Catalysts: Confirmation of future earnings, positive news on Phase 3 clinical trials (particularly on chronic pain), improvement in general macroeconomic sentiment, and absence of major negative news.

BASE Scenario (Probability 25%): The stock could remain in a consolidation phase around current levels, between $16.00 (SMA20/200) and $17.50, while fully digesting the results and profit-taking. Low current volume suggests investor waiting. High macroeconomic risks (Macro Risk Score 69/100) could hinder an immediate rebound. * Catalysts: Maintenance of macroeconomic status quo, absence of strong short-term microeconomic catalysts, and continued profit-taking.

BEARISH Scenario (Probability 15%): A break below the key support of $15.50 (1M support and SMA200) would invalidate the medium-term bullish thesis. This could be triggered by a deterioration in general market sentiment, doubts about product commercialization, or an unexpected failure in ongoing clinical trials. * Catalysts: Deterioration of general market sentiment, clinical trial failures, downward revision of growth forecasts, or significant increase in geopolitical/monetary risk.

AEGIS VERDICT

In a BULL regime (SPY > MA50 > MA200) with HIGH macro risk (Macro Risk Score 69/100), this BULLISH signal on MESO is based on significant fundamental potential and relative outperformance. Macro risk remains high, but the Risk/Reward ratio of 3.33:1 is favorable. The signal triggers on a close above $17.00. The intermediate target (TP1) is set at $19.36, with a final target (TP2) at $22.00. The stop-loss is positioned at $15.50. Recommended sizing: standard (1x).